Diagonal Bio AB (publ) (“Diagonal Bio” eller “Företaget”) meddelar att företaget har ingått ett avtal med en Hörsholms Hästepraksis rörande en testperiod som kliniken betalar för. Avtalet gäller användning av LAMPlify[TM]-systemet och innebär säkrande av den första kundintäkten för Diagonal.
Read moreDiagonal Bio AB (publ) (”Diagonal” eller ”Bolaget”) har satt upp fokusområden för sina teknologier LAMPlify™ (testsystemet på mindre reglerade marknadssegment) samt PANVIRAL™ (in-vitro-diagnostiksystem för infektionssjukdomar) och satt upp milstolpar för 2023. För att säkerställa framsteg mot dessa milstolpar har Bolaget kartlagt en marknadsförings- och försäljningsstrategi som beskrivs i en publicerad strategiuppdatering på Bolagets hemsida: https://diagonalbio.com/investors/focus2023.
Read moreStyrelsen i Diagonal Bio AB (publ.) (”Diagonal” eller ”Bolaget”) har utsett styrelseledamot Karin Wehlin som tillförordnad VD. Karin efterträder Jack Egelund Madsen i rollen som VD med omedelbar verkan efter att styrelsen och Jack gemensamt kommit överens om att han ska lämna uppdraget. Jack kommer att finnas tillgänglig för Bolagets ledning och styrelse under en övergångsperiod.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” eller “Bolaget”) meddelar att bolaget initierar en pilotstudie med Techtum Lab AB. Techtum Lab AB är en fullservicepartner till molekylärbiologiska laboratorium i Norden. Studien gäller identifiering av genetiska markörer för herpesvirus typ 1 och 4 samt influensavirus, för hästar, och kommer att utföras i ett veterinärlaboratorium i Stockholmsområdet. Efter en lyckad pilotstudie är nästa steg att intensifiera samarbetet och erbjuda Techtum Lab ett långsiktigt kommersiellt avtal för att distribuera LAMPlify[TM]-systemet.
Read moreDiagonal Bio AB (publ) (“Diagonal” eller “Bolaget”) offentliggör härmed delårsrapport för perioden 1 januari – 30 september 2023. Delårsrapporten finns tillgänglig som bifogat dokument samt på Bolagets hemsida (www.diagonalbio.com). Nedan följer en kort sammanfattning av rapporten.
Read more
Chair of the Board since 2023
On the board since: 2021
Background and Education: Kerstin Åkesson Jakobsson is a civil engineer with over 30 years of experience in marketing and sales, primarily in the Medtech sector, as well as in corporate management and business development. She has served as CEO for development companies such as SpectraCure AB and Ortoma AB, and CEO for Medicon Village Innovation. Jakobsson has also completed board training at EFL and the Board Academy.
Current Engagements: Senior Advisory of Kongsberg Beam Technology AS and CEO and chairman of Krakesson AB. Board member of the Stiftelsen TEM, QueenInvest AB, and OctaQuest AB.
Holdings in the Company:
Kerstin Jakobsson owns 19,045 shares.
Krakesson AB holds 240,516 shares.
Independent in relation to the Company and its management / major shareholders of the Company: Yes / No
Board Member
On the board since: 2023
Background and Education: Karin Wehlin has an Executive MBA degree from Lunds University and educated at INSEAD in Strategy, Innovation, and Leadership. Karin has over 25 years of experience in senior positions within the Life Science sector. She has served as CEO of Respiratorius AB, LU Food Science AB, and BoMill AB, as well as a Manager in Corporate Finance. Karin is also the founder of EQL Pharma AB, where she was the executive Chairman of the board for 10 years.
Current Engagements: Chair of the Board at Duearity AB and Respiratorius AB.
Holdings in the Company:
0 shares
Independent in relation to the Company and its management / major shareholders of the Company: No / Yes
Board Member
On the board since: 2021
Background and Education: Edvard Hall holds degrees in economics and law and is an entrepreneur with extensive experience in building and managing companies within the sustainability sector. Hall also has a master’s degree in political economy from the London School of Economics.
Current Engagements: CEO of Bioextrax AB (publ), Chairman of the Board for ProLevi Bio AB and Könvyes Invest AB, and Board Member of Parlametric AB.
Holdings in the Company: 358,000 shares and private capital invested in the Company.
Independent in relation to the Company and its management / major shareholders of the Company: Yes / Yes
Board Member
On the board since: 2020
Background and Education: Kushagr Punyani is educated in microfluidics and biosensors. Punyani has co-founded several startups in the tech industry alongside his role as Chief Scientific Officer (CSO) at Spermosens AB, a company specializing in diagnostic equipment and products for male fertility diagnostics and treatment.
Current Engagements: Board member at Spermosens AB, Prolevi Bio AB and Nested Bio AB.
Holdings in the Company:
Kushagr Punyani owns 1,876,000 shares and has private capital invested in the Company.
Nested Bio AB holds 110,292 shares.
Independent in relation to the Company and its management / major shareholders of the Company: Yes / No
Scheelevägen 17
223 63 Lund
Sweden
CEO since November 2023
Board Member since 2023
Learn more about her background and other engagements above.
CFO since 2021
Background and Education: Per Heander holds a degree in Business Administration from Lund University and has 20 years of experience as an Investment Manager in venture capital, with extensive experience in developing young growth companies and serving as a board member. Heander has served as CFO for various companies including Invent Medic, Bomill, and Benchtell AB. He also brings 10 years of experience from different positions within SEB.
Current Engagements: Board member at Gand AB, board member and CEO of Treeridge AB, and deputy board member of Fyra X Invest AB.
Holdings in the Company:
Per Heander owns 104,755 shares, of which 47,615 are through capital insurance.
Treeridge AB holds 473,677 shares.
Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 770 305 24 88
kw@diagonalbio.com
Svensk Kapitalmarknadsgranskning AB
www.skmg.se
Phone: +46 11 32 30 732
E-mail: ca@skmg.se
Nordic Issuing AB
Stortorget 3
211 22 Malmö
